ATP6V1B1 mutations in distal renal tubular acidosis and sensorineural hearing loss: clinical and genetic spectrum of five families

Asli Subasioglu Uzak1,2, Nilgun Cakar3, Elif Comak4, Fatos Yalcinkaya5, and Mustafa Tekin2,5

1Department of Medical Genetics, Erciyes University School of Medicine, Kayseri, Turkey
2Dr. John T. Macdonald Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, United States of America
3Department of Pediatrics, Ankara Diskapi Children’s Hospital, Ankara, Turkey
4Department of Pediatrics, Akdeniz University School of Medicine, Antalya, Turkey
5Department of Pediatrics, Ankara University School of Medicine, Ankara, Turkey

Abstract

Distal renal tubular acidosis (DRTA) is characterized by tubular defects in urinary acidification and hyperchloremic metabolic acidosis, hypokalemia, hypercalciuria, hypocitraturia, nephrocalcinosis and nephrolithiasis. Mutations in ATP6V1B1 cause DRTA associated with sensorineural hearing loss. The objective of this multicenter study is to screen DRTA patients with sensorineural hearing loss for ATP6V1B1 gene mutations and present genotype/phenotype correlation. Clinical data in five unrelated consanguineous families with DRTA and hearing loss were obtained in Turkey. For mutation screening, all coding exons of ATP6V1B1 were PCR amplified and sequenced from genomic DNA. In our cohort of five families, there were four different homozygous ATP6V1B1 mutations in affected individuals: c.91C>T (p.R31X), c.232G>A (p.G78R), c.497delC (p.T166RfsX9) and c.1155dupC (p.I386HfsX56). Our study shows that rare and family-specific variants in ATP6V1B1 are responsible for DRTA and sensorineural hearing loss syndrome in Turkey. While firm genotype–phenotype correlations are not available, detailed clinical and molecular analyses provide data to be used in genetic counseling.

Introduction

Distal renal tubular acidosis (DRTA) (MIM 267300) is caused by defective secretion of H+ ions by collecting tubule cells, which results in defects in urinary acidification. The disease

Correspondence to: Mustafa Tekin, 1501 NW 10th Avenue, BRB-610 (M-860) Miami, FL 33136, United States of America. Tel.: 305 243 2381, mtekin@med.miami.edu.

Declaration of interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. This work was supported by National Institutes of Health grant R01DC009645 to M.T.
is characterized by an elevation in urinary pH, despite the presence of systemic acidosis. Delayed growth, systemic acidosis with hyperchloremia, hypokalemia, hypocitraturia and hypercalciuria with nephrocalcinosis are also seen.\(^1\) Both autosomal recessive and dominant patterns of transmission have been observed. Mutations in the \textit{ATP6V1B1} gene encoding the B1 subunit of vacuolar H-ATPase result in autosomal recessive DRTA associated with sensorineural hearing loss (SNHL).\(^2\) The aim of this study was to identify \textit{ATP6V1B1} mutations in a cohort of Turkish patients with DRTA and SNHL. Here, we report on five unrelated families with DRTA and SNHL that showed four different \textit{ATP6V1B1} mutations.

**Materials and methods**

**Subjects**

For each affected individual, a detailed clinical examination was obtained including otologic evaluations, renal and kidney ultrasonography, arterial blood gas with electrolytes, kidney and liver function tests and routine blood and urine tests. All patients were diagnosed with DRTA based on clinical and laboratory findings (Table 1). Diagnosis of sensorineural hearing loss was established via standard audiometry. Audiograms of the probands showed that the hearing loss was severe in all affected individuals. Anamnestic evaluation and/or serial audiogram indicated that all of the patients had congenital/early onset hearing loss. Similar histories were present in elder siblings in families 631 and 423 who passed away when they were nearly 1 year old but were not investigated. Family members of affected individuals also received regular clinical evaluations to detect any symptoms that may be potentially associated with the disease or heterozygosity for the disorder. This study was approved by Ankara University Ethics Committee and by the Institutional Review Board at the University of Miami. A signed informed consent was obtained from each participant or a parent.

**Mutation analysis**

The 14 coding exons of \textit{ATP6V1B1} (NM_001692.3) were PCR amplified using primer sets designed by the primer 3.0 software (Cambridge, MA). The list of primers is available upon request. PCR reactions were run in 25 mL volume applying a touch-down protocol and annealing temperatures between 65 °C and 57 °C. PCR products were visualized on agarose gels, cleaned over Sephadex columns followed by BigDye reactions performed according to the manufacturer’s recommendations (Applied Biosystems Inc., Foster City, CA). A DNA Sequencer (ABI 3730xl) (Applied Biosystems Inc., Foster City, CA) was used to detect mutations. Results were visualized with the Sequencher 4.7 software (Gene Codes Corporation, Ann Arbor, MI).

**Results**

Details of clinical findings in five probands are shown in Table 1. Parents were first cousins in all five families. Laboratory evaluations in unaffected family members were normal. DNA sequencing showed four previously reported \textit{ATP6V1B1} mutations (Figure 1). All mutations were homozygous in affected children and co-segregated as a fully penetrant autosomal recessive trait in each family. Identified mutations were c.91C4T (p.R31X) in Family 153, c.
232G4A (p.G78R) in Family 423, c.497delC (p.T166RfsX9) in Family 631 and c.1155dupC (p.I386HfsX56) in Families 642 and 953 (Figure 1).

**Discussion**

Nance and Sweeney demonstrated for the first time that DRTA with SNHL was a distinct entity with autosomal recessive inheritance.\(^3\) ATP6V1B1 (MIM 192132) mutations have subsequently shown to cause DRTA with SNHL syndrome.\(^4\) Patients with ATP6V1B1 mutations usually present at an early age (the majority was diagnosed by age 1 year) with either dehydration and vomiting, or with failure to thrive and/or delayed growth. The clinical diagnosis is based on inappropriately high urinary pH despite the presence of serum acidosis with normal anion gap, evidence of hypokalemia and no evidence of secondary causes of DRTA. While hypercalciuria with nephrocalcinosis is seen in almost all cases, renal function usually remains normal with proper and early treatment. Bilateral progressive sensorineural hearing loss ranging from mild to profound is present in the majority of patients. ATP6V1B1 encodes the B1 subunit of the apical proton pump, mediating distal nephron acid secretion.\(^4\) The H\(^+\)-adenosine triphosphatase (ATPase) in the apical border of the intercalated cell of the distal nephron has a multisubunit structure that plays a role in pumping H\(^+\) into the tubular lumen.\(^5\) To date, 26 ATP6V1B1 mutations have been determined as the cause of the disease.\(^4,6-13\) These include missense, nonsense, deletion, insertion and splice site changes, all of which are predicted to disrupt the structure or abrogate the production, of the normal B1 subunit protein. This leads to loss of expression of the gene in the distal tubules as well as in cochlea and endolympathic sac. Active proton secretion is required to maintain proper endolymph pH and normal auditory function.\(^2\) While the ATP6V1B1 knockout mouse model has been generated and was shown to develop incomplete DRTA, it has normal ear morphology and function, making the pathophysiology of SNHL somewhat unclear.\(^14\) The ATP6V0A4 gene encodes a 4-subunit portion of the H\(^+\)-ATPase in which mutations may also cause DRTA. Studies to date have shown that mutations in ATP6V1B1 cause DRTA with SNHL, whereas mutations in ATP6V0A4 cause DRTA with either normal hearing or later onset hearing loss.\(^4,12,15\) The C to T transition at nucleotide position 91 (c.91C\(\rightarrow\)T) found in family 153 results in a stop codon at amino acid 31 (p.R31X). Homozygous p.R31X was originally reported in three unrelated families from Turkey and Spain, but clinical aspects of these families were not reported.\(^4\) In a subsequent report, two children with the homozygous p.R31X mutation had features of DRTA with failure to thrive, polyuria, refractory rickets, hypokalemia and nephrocalcinosis as well as severe SNHL.\(^2\) Clinical features in our study similarly show severe and early presentation of kidney and ear findings. And also severe growth deficiency can be due to noncompliance with the treatment. The c.1155dupC (p.I386HfsX56) mutation was found in two unrelated families in this study. This mutation was initially reported in North Africa, Saudi Arabia and also in Sicily, suggesting a founder effect.\(^8\) The presence of the same mutation in two unrelated families in Turkey supports the idea of a founder mutation that spread out with population movements. It also suggests that c.1155dupC is relatively common. The p.G78R mutation was first described in two Turkish families.\(^7\) Clinical findings in the original report included four affected children with DRTA and SNHL. Although all four cases showed clinical findings of DRTA, three patients manifested radiographic changes of osteopetrosis.
Subsequently osteopetrosis was found to be the result of a homozygous deletion in TCIRG1, which encodes an osteoclast specific isoform of subunit α of the H⁺-ATPase, while the DRTA was associated with a homozygous mutation in \textit{ATP6V1B1}. The c.497delC (p.T166RfsX9) mutation that was found in family 631 is a single base-pair deletion at codon 166 causing a frame shift and resulting in premature termination at codon 174. It was first reported in a 1-month-old boy who had hearing loss and laboratory findings compatible with DRTA. This mutation was also later identified in a consanguineous family from Saudi Arabia. We conclude that while genotype–phenotype correlations for \textit{ATP6V1B1} mutations are not clearly established, detailed clinical and molecular analyses help in clinical setting for predicting outcome of patients with the same mutation. The aims of the treatment of DRTA must be to correct biochemical abnormalities, improve growth and prevent nephrocalcinosis that can lead to chronic renal failure and skeletal abnormalities. While early treatment corrects the biochemical abnormalities and helps to foster normal growth, deafness appears not to be prevented. Thus, early diagnosis of SNHL is important to improve speech, intellectual development and social communication skills of the affected children.

\section*{Acknowledgments}

We are grateful to the family members for their participation in this study.

\section*{References}


Figure 1.
Pedigrees along with segregation of identified mutations. Electropherograms of each mutation is provided.
Table 1
Clinical and laboratory findings of the five probands with DRTA and hearing loss.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at last control (years)</td>
<td>14</td>
<td>16</td>
<td>16</td>
<td>12</td>
<td>16</td>
</tr>
<tr>
<td>Age at diagnosis (months)</td>
<td>1</td>
<td>2.5</td>
<td>1.5</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>Sex</td>
<td>Male</td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>2850</td>
<td>4000</td>
<td>2730</td>
<td>3500</td>
<td>2000</td>
</tr>
<tr>
<td>Presenting clinical manifestations</td>
<td>Weakness, hypotonicity, dehydration</td>
<td>Weakness, hypotonicity</td>
<td>Vomiting, dehydration</td>
<td>Growth and developmental delay, constipation</td>
<td>Weakness, hypotonicity</td>
</tr>
<tr>
<td>Weight SDS at last control</td>
<td>−3.664</td>
<td>−1.243</td>
<td>−1.363</td>
<td>−1.369</td>
<td>−1.746</td>
</tr>
<tr>
<td>Height SDS at last control</td>
<td>−3.914</td>
<td>−2.071</td>
<td>−2.170</td>
<td>−1.189</td>
<td>−2.562</td>
</tr>
<tr>
<td>Medullary nephrocalcinosis</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Severe sensorineural deafness</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Biochemical findings at diagnosis</td>
<td>Blood pH (7.35–7.45)</td>
<td>7.10</td>
<td>7.30</td>
<td>7.30</td>
<td>7.23</td>
</tr>
<tr>
<td></td>
<td>Urine pH (5–7)</td>
<td>7</td>
<td>8</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Serum creatinine (0.5–1.4 mg/dL)</td>
<td>0.5</td>
<td>0.6</td>
<td>0.7</td>
<td>0.5</td>
</tr>
<tr>
<td></td>
<td>Sodium (135–147 mEq/L)</td>
<td>140</td>
<td>138</td>
<td>130</td>
<td>147</td>
</tr>
<tr>
<td></td>
<td>Potassium (3.5–5 mEq/L)</td>
<td>1.9</td>
<td>1.9</td>
<td>2.2</td>
<td>1.8</td>
</tr>
<tr>
<td></td>
<td>Bicarbonate (23–29 mEq/L)</td>
<td>8</td>
<td>17</td>
<td>15</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>Serum anion gap&lt;sup&gt;2&lt;/sup&gt; (6–14 mEq/L)</td>
<td>10</td>
<td>12</td>
<td>11</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>Phosphate (2.4–4.1 mg/dL)</td>
<td>3</td>
<td>3</td>
<td>2.8</td>
<td>3.5</td>
</tr>
<tr>
<td></td>
<td>Alkaline phosphatase (38–126 U/L)</td>
<td>15</td>
<td>13</td>
<td>15</td>
<td>16</td>
</tr>
</tbody>
</table>

<sup>1</sup> Normal range is given in parenthesis;

<sup>2</sup> Serum anion gap = Na<sup>+</sup> – (Cl<sup>−</sup> + HCO<sup>−</sup>);

SDS, standard deviation score; N/A, not available.